OnabotulinumtoxinA for the treatment of headache

Headache

Volumn 53, Issue SUPPL.2, 2013, Pages 54-61

  Ashkenazi, Avi ^a   Blumenfeld, Andrew ^b  

^a Doylestown Hospital   (United States)

^b Neurology Center   (United States)

Author keywords

Chronic migraine; Headache; Injection; OnabotulinumtoxinA

Indexed keywords

CHRONIC MIGRAINE; HEADACHE; INJECTION; ONABOTULINUMTOXINA;

ANIMALS; BOTULINUM TOXINS, TYPE A; HEADACHE; HUMANS; INJECTIONS, INTRAMUSCULAR; TREATMENT OUTCOME;

EID: 84893919865     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/head.12185     Document Type: Article

References (43)

1. Turton K, Chaddock JA, Acharya KR. Botulinum and tetanus neurotoxins: Structure, function and therapeutic utility. Trends Biochem Sci. 2002;27: 552-558.
2. Shapiro RL, Hatheway C, Swerdlow DL. Botulism in the United States: A clinical and epidemiologic review. Ann Intern Med. 1998;129: 221-228.
3. Jankovic J, Brin MF. Therapeutic uses of botulinum toxin. N Engl J Med. 1991;324: 1186-1194.
4. Binder WJ, Brin MF, Blitzer A, et al. Botulinum toxin type A (BOTOX) for treatment of migraine headaches: An open-label study. Otolaryngol Head Neck Surg. 2000;123: 669-676.
5. McMahon HT, Foran P, Dolly JO, et al. Tetanus toxin and botulinum toxins type A and B inhibit glutamate, gamma-aminobutyric acid, aspartate, and met-enkephalin release from synaptosomes. Clues to the locus of action. J Biol Chem. 1992;267: 21338-21343.
6. Welch MJ, Purkiss JR, Foster KA. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon. 2000; 38: 245-258.
7. Ashkenazi A, Silberstein SD. Botulinum toxin and other new approaches to migraine therapy. Annu Rev Med. 2004;55: 505-518.
8. Ashkenazi A, Levin M, Dodick DW. Peripheral procedures: Nerve blocks, peripheral neurostimulation and Botulinum neurotoxin injections. In: Silberstein SD, Lipton RB, Dodick DW, eds. Wolff's Headache and Other Head Pain. New York: Oxford University Press; 2007: 767-792.
9. Dolly O. Synaptic transmission: Inhibition of neurotransmitter release by botulinum toxins. Headache. 2003;43(Suppl. 1): S16-S24.
10. Cui M, Khanijou S, Rubino J, et al. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain. 2004;107: 125-133.
11. Durham PL, Cady R, Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: Implications for migraine therapy. Headache. 2004; 44: 35-42.
12. Antonucci F, Rossi C, Gianfranceschi L, et al. Longdistance retrograde effects of botulinum neurotoxin A. J Neurosci. 2008;28: 3689-3696.
13. Ranoux D, Attal N, Morain F, et al. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann Neurol. 2008;64: 274-283.
14. Yuan RY, Sheu JJ, Yu JM, et al. Botulinum toxin for diabetic neuropathic pain: A randomized double-blind crossover trial. Neurology. 2009;72: 1473-1478.
15. Brin MF. Botulinum toxin: Chemistry, pharmacology, toxicity, and immunology. Muscle Nerve Suppl. 1997;6: S146-S168.
16. Smuts JA, Schultz D, Barnard A. Mechanism of action of botulinum toxin type A in migraine prevention: A pilot study. Headache. 2004;44: 801-805.
17. Behmand RA, Tucker T, Guyuron B. Single-site botulinum toxin type a injection for elimination of migraine trigger points. Headache. 2003;43: 1085-1089.
18. Silberstein S, Mathew N, Saper J, et al. Botulinum toxin typeA as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group. Headache. 2000;40: 445-450.
19. Evers S, Vollmer-Haase J, Schwaag S, et al. Botulinum toxin A in the prophylactic treatment of migraine -a randomized, double-blind, placebocontrolled study. Cephalalgia. 2004;24: 838-843.
20. Aurora SK, Gawel M, Brandes JL, et al. Botulinum toxin type a prophylactic treatment of episodic migraine: A randomized, double-blind, placebocontrolled exploratory study. Headache. 2007;47: 486-499.
21. Relja M, Poole AC, Schoenen J, et al.A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches. Cephalalgia. 2007; 27: 492-503.
22. Jackson JL, Kuriyama A, Hayashino Y. Botulinum toxin A for prophylactic treatment of migraine and tension headaches in adults: A meta-analysis. JAMA. 2012;307: 1736-1745.
23. Ondo WG, Vuong KD, Derman HS. Botulinum toxin A for chronic daily headache: A randomized, placebo-controlled, parallel design study. Cephalalgia. 2004;24: 60-65.
24. Mathew NT, Frishberg BM, Gawel M, et al. Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: A randomized, double-blind, placebo-controlled trial. Headache. 2005;45: 293-307.
25. Dodick DW, Mauskop A, Elkind AH, et al. Botulinum toxin type A for the prophylaxis of chronic daily headache: Subgroup analysis of patients not receiving other prophylactic medications: A randomized double-blind, placebo-controlled study. Headache. 2005;45: 315-324.
26. Silberstein SD, Stark SR, Lucas SM, et al. Botulinum toxin type A for the prophylactic treatment of chronic daily headache: Arandomized,double-blind, placebo-controlled trial. Mayo Clin Proc. 2005; 80: 1126-1137.
27. Ashkenazi A. Botulinum toxin type A for chronic migraine. Curr Neurol Neurosci Rep. 2010;10: 140-146.
28. Aurora SK, Dodick DW, Turkel CC, et al. OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebocontrolled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30: 793-803.
29. Diener HC, Dodick DW, Aurora SK, et al. OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30: 804-814.
30. Dodick DW, Turkel CC, Degryse RE, et al. OnabotulinumtoxinA for treatment of chronic migraine: Pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010;50: 921-936.
31. FDA approves Botox to treat chronic migraine. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm229782.htm 2013. (accessed May 11, 2013).
32. Ondo WG, Gollomp S, Galvez-Jimenez N. A pilot study of botulinum toxin A for headache in cervical dystonia. Headache. 2005;45: 1073-1077.
33. Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders: 2nd edition. Cephalalgia. 2004;24(Suppl. 1): 9-160.
34. Dowson AJ, Kilminster SG, Salt R. Clinical profile of botulinum toxin A in patients with chronic headaches and cervical dystonia: A prospective, openlabel, longitudinal study conducted in a naturalistic clinical practice setting. Drugs R D. 2008;9: 147-158.
35. Winner PK, Sadowsky CH, Martinez WC,et al. Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine. Headache. 2012; 52: 1219-1225.
36. Jensen R, Olesen J. Tension-type headache: An update on mechanisms and treatment. Curr Opin Neurol. 2000;13: 285-289.
37. Rollnik JD,Tanneberger O, Schubert M, et al.Treatment of tension-type headache with botulinum toxin type A: A double-blind, placebo-controlled study. Headache. 2000;40: 300-305.
38. Padberg M, de Bruijn SF, de Haan RJ, et al. Treatment of chronic tension-type headache with botulinum toxin: A double-blind, placebo-controlled clinical trial. Cephalalgia. 2004;24: 675-680.
39. Schulte-Mattler WJ, Krack P. Treatment of chronic tension-type headache with botulinum toxin A: A randomized, double-blind, placebo-controlled multicenter study. Pain. 2004;109: 110-114.
40. Mathew NT, Kailasam J, Meadors L. Botulinum toxin type A for the treatment of nummular headache: Four case studies. Headache. 2008;48: 442-447.
41. Freund BJ, Schwartz M. Treatment of chronic cervical-associated headache with botulinum toxin A: A pilot study. Headache. 2000;40: 231-236.
42. Blumenfeld A, Silberstein SD, Dodick DW, et al. Method of injection of onabotulinumtoxinA for chronic migraine: A safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program. Headache. 2010;50: 1406-1418.
43. Eross EJ, Gladstone JP, Lewis S, et al. Duration of migraine is a predictor for response to botulinum toxin type A. Headache. 2005;45: 308-314.